Supervitamins

SuperVitamins is an Israeli biotechnology company focused on the development of mitocans, which are small molecules designed to target and disrupt the mitochondria of cancer cells. The company's lead candidate, SV-101, is a proprietary derivative of Vitamin E (alpha-tocopheryl succinate) that selectively induces apoptosis in malignant cells by generating reactive oxygen species and interfering with mitochondrial function. Founded by Professor Shimon Slavin, a prominent figure in immunotherapy and regenerative medicine, the company aims to create non-toxic cancer therapies that can be used as monotherapies or in combination with standard treatments. SuperVitamins' research extends to the treatment of inflammatory conditions where mitochondrial dysfunction plays a key role. The company's approach leverages the natural properties of vitamins, modified to enhance their therapeutic efficacy and bioavailability.